2QV Stock Chart & Stats
€2.94
€0.00(0.00%)
At close: 4:00 PM EDT
€2.94
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.86 - €3.48
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.68M
Enterprise Value€4.48
Total Cash (Recent Filing)€8.04M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.01Price Target Upside342.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces solvency and interest-service risk for a clinical-stage biotech. This structural strength preserves strategic optionality to fund trials, pursue partnerships, or absorb delays without immediate creditor pressure, improving resilience over the next 2–6 months.
Merger Provides Capital RunwayThe announced stock‑for‑stock merger and $30M committed financing materially extends Chemomab’s cash runway and reduces near‑term financing risk. The combined entity adds revenue and scale, supporting Phase 2 RA plans and lowering execution risk for nebokitug over the medium term.
Encouraging Nebokitug Clinical SignalsTranslational biomarker and dose-response data from SPRING provide mechanistic and efficacy signals that increase the likelihood of successful advancement or partnering. Durable clinical evidence strengthens commercial and alliance value in PSC and related indications.
Bears Say
Pre-revenue Operating LossesThe company remains pre‑revenue with persistent operating losses, meaning it lacks internal product cashflow to fund development. Over the medium term this structurally increases dependence on external capital and magnifies execution and timing risks tied to clinical readouts.
Sustained Cash BurnOngoing negative operating and free cash flow forces repeated financing rounds or strategic deals to sustain R&D. Even with improved 2025 trends, structural cash‑consumption raises dilution and timing risk if capital markets become less accessible before revenue or major milestones.
Authorized Capital Increase / Dilution RiskBoard‑approved expansion of authorized share capital is a structural enabler for future equity issuances. That flexibility, while useful for funding, signals potential dilution for existing holders and can increase cost of capital and shareholder dilution risk across the next several financing events.
Chemomab Therapeutics News
2QV FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was €2.86 and its highest was €3.48 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is €9.68M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -€0.003 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in DE:2QV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
2QV Stock 12 Month Forecast
Average Price Target
€13.01
▲(342.40% Upside)